In a nutshell The aim of this study was to compare the heath related quality of life (HRQOL) of patients treated with enzalutamide (Xtandi) or bicalutamide (Casodex). It was concluded that enzalutamide led to a better HRQOL in patients with metastatic castration resistant prostate cancer when compared...
Read MoreIn a nutshell This study determined whether a faster course of salvage chemotherapy reduced tumor volume in patients with relapsed or refractory Hodgkin lymphoma. The authors concluded that shorter intervals between SC cycles was safe and effective. Some background Hodgkin lymphoma is considered to be a highly curable form of...
Read More
In a nutshell This study examined the use of nivolumab (Opdivo) in patients with heavily pretreated Hodgkin lymphoma. The authors concluded that nivolumab was effective and safe in these patients. Some background PD-1 is a protein that slows the immune response. Many cancer cells use the PD-1 pathway to block the immune system from attacking...
Read More
In a nutshell This review summarized evidence on emerging immunotherapies for prostate cancer. Authors concluded that immunotherapeutic agents show promising early results in patients with advanced prostate cancer and few symptoms. Some background Immunotherapies are currently under investigation as possible cancer treatments. Immunotherapies...
Read More
In a nutshell This phase 2 trial aims to compare the benefit of two types of exercise for men with metastatic castration-resistant prostate cancer. The main outcome to be investigated is the safety of the exercises and its effect on cancer pain. The trial is recruiting in San Francisco (California). The details Metastatic castration-resistant...
Read More
In a nutshell This study examined the safety and effectiveness of radium-223, alone or in combination with other therapies, in treating metastatic castration-resistant prostate cancer (mCRPC). Researchers concluded that radium-223 was well tolerated and can be safely combined with additional therapies. Combined therapies were associated with improved...
Read MoreIn a nutshell This study compared immediate and delayed androgen deprivation therapy (ADT) for men with relapsed or non-curable prostate cancer. Authors reported improved survival and disease progression with immediate ADT. Some background ADT is a type of hormone therapy used to treat prostate cancer. It targets the production of male hormones...
Read More
In a nutshell This study compared the safety and effectiveness of afatinib (Gilotrif) and erlotinib (Tarceva) as second-line treatments for advanced squamous cell carcinoma (SCC). Authors reported improved survival and disease progression with afatinib compared to erlotinib. Both treatments were associated with a good safety profile. Some background...
Read More
In a nutshell This study investigated the safety and effectiveness of the drug eribulin (Halaven) for the treatment of patients with metastatic breast cancer and resistance to taxane therapies. The study concluded that eribulin was effective and well tolerated in patients with metastatic breast cancer. Some background Taxanes are a type of...
Read More
In a nutshell This study examined whether switching steroid drugs during secondary hormone therapy with abiraterone (Zytiga) improves treatment response in progressing, advanced prostate cancer. Researchers concluded that a steroid switch can be effective in delaying disease progression in some men. Some background Abiraterone is a secondary...
Read More
In a nutshell The authors aimed to determine whether palbociclib (Ibrance) could help treat women hormone-receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) metastatic (cancer has spread) breast cancer. The addition of palbociclib showed consistent success against breast cancer that had become resistant...
Read More
In a nutshell The authors evaluated the effectiveness of the combination treatment of AdCD40L (a gene therapy and chemotherapy) in advanced melanoma. The authors found out that the gene therapy was well tolerated with beneficial treatment outcome. Some background In advanced melanoma (stage 3 or 4), the cancer spreads from the skin to...
Read More
